SQL Server 2025 delivers major performance upgrades alongside licensing changes that can reshape both operational speed and budget strategy. Smarter query execution, refined CPU scheduling, and better ...
FDA approval was supported by the one-year results of the TRIOMPHE Investigational Device Exemption (IDE) Study evaluating the NEXUS® System shown to effectively treat aortic arch disease, including ...
Artivion, Inc. AORT recently announced that the FDA has approved the premarket approval application for the NEXUS Aortic Arch System. Developed in partnership with Endospan Ltd., this innovative ...
ATLANTA - Artivion, Inc. (NYSE:AORT) announced today that the U.S. Food and Drug Administration has approved the premarket approval application for the NEXUS Aortic Arch System, developed by Endospan ...
TEL AVIV, Israel, April 07, 2026--(BUSINESS WIRE)--Endospan, a privately-held company pioneering solutions for the endovascular repair of aortic arch disease, today announced that the U.S. Food and ...
Endospan's NEXUS branched endovascular stent graft system shown to effectively treat aortic arch disease, including chronic aortic dissections ATLANTA, April 7, 2026 /PRNewswire/ -- Artivion, Inc.
Endospan's NEXUS branched endovascular stent graft system shown to effectively treat aortic arch disease, including chronic aortic dissections ATLANTA, April 7, 2026 /PRNewswire/ -- Artivion, Inc.
Artivion, Inc., a leading cardiac and vascular surgery company focused on aortic disease, announced that the US Food and Drug Administration (FDA) has approved the premarket approval application (PMA) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results